Evidence map›Paper›PMID 36155957›Full record

Observational studyEBioMedicine2022

Long COVID symptoms in exposed and infected children, adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational cohort study.

Anneke Haddad, Aleš Janda, Hanna Renk, Maximilian Stich, Pauline Frieh, Klaus Kaier, Florens Lohrmann, Alexandra Nieters, Anna Willems, Daniela Huzly and 21 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Long COVID: Long-Term Impact of SARS-CoV2.Diagnostics (Basel, Switzerland) · 2024
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 8 institutions in 1 country.

Anneke HaddadCenter for Pediatrics and Adolescent Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Aleš JandaDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Germany.
Hanna RenkUniversity Children's Hospital Tuebingen, Tuebingen, Germany.
Maximilian StichDepartment of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Pauline FriehCenter for Pediatrics and Adolescent Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Klaus KaierInstitute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Florens LohrmannCenter for Pediatrics and Adolescent Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany; Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; IMM-PACT Clinician Scientist Programme, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Alexandra NietersInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Anna WillemsCenter for Pediatrics and Adolescent Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Daniela HuzlyInstitute of Virology, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany.
Alex DulovicNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Nicole Schneiderhan-MarraNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Eva-Maria JacobsenDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Germany.
Dorit FabriciusDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Germany.
Maria ZernickelDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Germany.
Thomas StammingerInstitute of Virology, Ulm University Medical Center, Ulm, Germany.
Sebastian F N BodeDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Germany.
Theda HimpelUniversity Children's Hospital Tuebingen, Tuebingen, Germany.
Jonathan RemppisUniversity Children's Hospital Tuebingen, Tuebingen, Germany.
Corinna EngelCentre for Paediatric Clinical Studies, University Children's Hospital Tübingen, Tübingen, Germany.
Andreas PeterInstitute for Clinical Chemistry and Pathobiochemistry, University Hospital Tübingen, Tübingen, Germany.
Tina GanzenmuellerInstitute for Medical Virology and Epidemiology of Viral Diseases, University Hospital Tübingen, Tübingen, Germany.
Georg Friedrich HoffmannDepartment of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Bettina HaaseDepartment of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Hans-Georg KräusslichDepartment of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany.
Barbara MüllerDepartment of Infectious Diseases, Virology, Heidelberg University, Heidelberg, Germany.
Axel R FranzUniversity Children's Hospital Tuebingen, Tuebingen, Germany; Centre for Paediatric Clinical Studies, University Children's Hospital Tübingen, Tübingen, Germany.
Klaus-Michael DebatinDepartment of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm University, Germany.
Burkhard TönshoffDepartment of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Philipp HennekeCenter for Pediatrics and Adolescent Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany; Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Roland EllingCenter for Pediatrics and Adolescent Medicine, Medical Center and Faculty of Medicine, University of Freiburg, Freiburg, Germany; Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Electronic address: roland.elling@uniklinik-freiburg.de.
Heidelberg University · DEUniversität Ulm · DEUniversity Children's Hospital Tübingen · DEUniversity of Freiburg · DEUniversity Medical Center Freiburg · DENatural and Medical Sciences Institute · DEInstitute of Medical Microbiology and Hygiene · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong COVID in children and adolescents remains poorly understood due to a lack of well-controlled studies with long-term follow-up. In particular, the impact of the family context on persistent symptoms following SARS-CoV-2 infection remains unknown. We examined long COVID symptoms in a cohort of infected children, adolescents, and adults and their exposed but non-infected household members approximately 1 year after infection and investigated clustering of persistent symptoms within households.

methods1267 members of 341 households (404 children aged <14 years, 140 adolescents aged 14-18 years and 723 adults) were categorized as having had either a SARS-CoV-2 infection or household exposure to SARS-CoV-2 without infection, based on three serological assays and history of laboratory-confirmed infection. Participants completed questionnaires assessing the presence of long COVID symptoms 11-12 months after infection in the household using online questionnaires.

findingsThe prevalence of moderate or severe persistent symptoms was statistically significantly higher in infected than in exposed women (36.4% [95% CI: 30.7-42.4%] vs 14.2% [95% CI: 8.7-21.5%]), infected men (22.9% [95% CI: 17.9-28.5%] vs 10.3% [95% CI: 5.8-16.9%]) and infected adolescent girls (32.1% 95% CI: 17.2-50.5%] vs 8.9% [95%CI: 3.1-19.8%]). However, moderate or severe persistent symptoms were not statistically more common in infected adolescent boys aged 14-18 (9.7% [95% CI: 2.8-23.6%] or in infected children <14 years (girls: 4.3% [95% CI: 1.2-11.0%]; boys: 3.7% [95% CI: 1.1-9.6%]) than in their exposed counterparts (adolescent boys: 0.0% [95% CI: 0.0-6.7%]; girls < 14 years: 2.3% [95% CI: 0·7-6·1%]; boys < 14 years: 0.0% [95% CI: 0.0-2.0%]). The number of persistent symptoms reported by individuals was associated with the number of persistent symptoms reported by their household members (IRR=1·11, p=·005, 95% CI [1.03-1.20]).

interpretationIn this controlled, multi-centre study, infected men, women and adolescent girls were at increased risk of negative outcomes 11-12 months after SARS-CoV-2 infection. Amongst non-infected adults, prevalence of negative outcomes was also high. Prolonged symptoms tended to cluster within families, suggesting family-level interventions for long COVID could prove useful.

fundingMinistry of Science, Research and the Arts, Baden-Württemberg, Germany.

Indexed as

COVID-19AdolescentAdultChildFemaleHumansMaleParentsPost-Acute COVID-19 SyndromeProspective StudiesSARS-CoV-2AdolescentsChildren and young peopleCOVID-19FamiliesLong COVIDPaediatricPost-COVID syndromeSARS-CoV-2

Identifiers

PMID36155957
PMCPMC9495281
OpenAlexW4296903697

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.